Sanuwave confirms acting CEO Richardson as company head | Personnel Moves – December 12, 2018

Sanuwave CEO Kevin Richardson

Sanuwave said late last month that it lifted acting CEO and board chair Kevin Richardson to a permanent position in the corner office.

Richardson joined the Suwanee, Ga.-based company in 2009 as board chair, and has served as acting CEO since 2014. He also served as managing partner of investment management firm Prides Capital from 2004 to September 2018.

Sanuwave said that Richardson took over as the permanent CEO as of November 30, and that he will continue to serve as board chair alongside his new position heading the company, according to an SEC filing.

 Common Sensing lifts Schmid to CEO, White to board chair

Common Sensing said late last month it lifted COO and board member Kevin Schmid to the role of CEO, and that it appointed co-founder James White as its board chair.

Prior to joining Common Sensing, Schmid held “pivotal roles” at Insulet (NSDQ:PODD), Bose, JDS Uniphase and the Stevanato Group and served as a board member for Sorrel Medical.

“Kevin’s appointment to the chief executive role puts Common Sensing in a very strong position to scale Gocap injector monitoring platforms for insulin and beyond. As we transition from pilot level to commercial level operations over the next year, Kevin’s transformative leadership of the talented and growing Common Sensing team will evolve and drive the execution of our go-to-market strategies for our patented dose sensing technology. Our goal is to provide a smart dose sensing platform for patients, health care providers and payers to embrace injectable medicines for home use,” White said in a prepared statement.

During his time with Insulet, Schmid aided in the development, industrialization and commercialization of wearable, smart drug delivery pumps, Cambridge, Mass.-based Common Sensing said.

Common Sensing said that Schmid will lead top-level strategy, expansion and investor relations, while prez and co-founder Richard Whalley will focus on clinical, quality and regulatory functions.

“We are well underway with the development of our high performance, scalable, and commercial Gen 2 Gocap platform. This, combined with insightful user data from existing studies and patients, lays the foundation for Gocap technology to make a tremendous impact on wireless integrated health care. Gocap is an easy-to-use, cost-effective dose monitoring and reporting solution which will be accessible to millions of self-injecting patients,” Schmid said in a press release.

Read more

 Glympse Bio appoints former Bristol-Myers exec Loew as prez & CEO

Glympse Bio said early this month that it appointed former Bristol-Myers Squibb (NYSE:BMY) exec Dr. Caroline Loew as its new prez & CEO.

Most recently, Loew served as R&D, strategy and planning VP at Bristol-Myers Squibb, the Cambridge, Mass.-based company said. She has also held senior roles with Merck and PhRMA, leading teams in drug development ,regulatory policy, market access and commercial fronts, Glympse Bio said.

“I’m excited to join Glympse and work alongside the exceptional and dedicated team here. Glympse’s powerful, tunable platform technology has the ability to transform how we detect and manage disease, and help both improve and save patients’ lives. I’m looking forward to building the company and fully realizing the potential of this platform for patients,” Loew said in a press release.

In connection with the appointment, Loew will also join Glympse Bio’s board of directors, which the company said it recently expanded. The expansion includes that appointment of co-founder Dr. Sangeeta Bhatia as head of the scientific advisory board and the appointment of Stanley Lapidus as board chair and Robert Langer as a board member.

“Caroline is an outstanding leader who brings a wealth of experience in life sciences, and we are thrilled she is joining Glympse. She is recognized for her acumen and operational execution, her ability to build talented teams and lead organizations, and for strategic development and commercialization of important products that change patients’ lives. We are also fortunate to have Sangeeta’s continuing scientific and clinical leadership on the Scientific Advisory Board,” board member & LS Polaris Innovation Fund partner Amy Schulman said in a prepared release.

Read more

 NovaDip Biosciences taps former Argos CEO Abbey as chief exec

Regenerative medicine company Novadip Bioscences said today that it named former Argos Therapeutics prez & CEO Jeff Abbey as its new CEO, succeeding Jean-François Pollet.

Abbey spent 15 years at immuno-oncology cell therapy company Argos Therapeutics, holding the position of president and CEO during the past eight years, Belgium-based Novadip said. During his time with Argos, Abbey guided the company through a phase 3 trial and helped raise $250 million in equity financings which included an initial public offering.

“With his extensive experience in cell therapy combined with his expertise in equity financing, business development and strategy, Jeff possesses the skills necessary to lead Novadip through the next phases of its development. The board is highly confident that Jeff’s wealth of international experience and proven leadership will help Novadip in its mission to become a leading regenerative medicine company. As the founding CEO, Jean-François Pollet, along with co-founder and CSO, Denis Dufrane, has led Novadip through a number of important milestones and positioned the company in a strong position to succeed. The board would like to express its gratitude to Jean-François Pollet,” board chair Eric Pâques said in a prepared statement.

Novadip is developing an autologous three-dimensional cell therapy that is currently being studied in a phase I/IIa trial in spinal fusion patients, the company said. It added that it recently launched a second clinical program looking to enroll patients with non-healing bone fractures and that it is developing a regenerative skin product based on its cell therapy platform.

“I am excited to have the opportunity to join Novadip The technology platform and portfolio of products the company is developing offer tremendous opportunities to provide unique solutions to patients with catastrophic conditions in the fields of bone disease and skin regeneration. I look forward to working with the founders and the outstanding team of Novadip to bring truly innovative therapies to market and build a preeminent biotechnology company,” Abbey said in a press release.

Read more

 Owens & Minor lifts interim CFO Snead to permanent chief finance officer position

Owens & Minor (NYSE:OMI) said today that it lifted interim CFO Robert Snead into a permanent role as chief financial officer and exec VP, effective December 6.

Snead has served as interim CFO since June, and will continue to report to board chair and interim prez & CEO Robert Sledd, the Richmond, Va.-based company said. He joined Owens & Minor in 2010 as corp dev VP and has held positions including treasurer and global solutions strategic biz unit finance group VP, the company added.

Prior to joining Owens & Minor, Snead served as Barclays Capital M&A group director in New York, the company said.

“We are very pleased Robert is taking on this important, strategic role for Owens & Minor. Robert’s eight years of service to Owens & Minor in a variety of finance and strategy roles have prepared him well for this leadership position. He brings valuable experience in working with the investor community, providing disciplined financial management oversight, and partnering with other leaders to help drive operating efficiency and profitability. Without question, Robert is the right choice for Owens & Minor as we prepare for the future,” board chair and interim prez & CEO Sledd said in a press release.

Read more

The post Sanuwave confirms acting CEO Richardson as company head | Personnel Moves – December 12, 2018 appeared first on MassDevice.

FDA grants breakthrough status to joint Merck-Bayer AI program

FDA-logo-newMerck and Bayer have been granted FDA Breakthrough Device Designation for the collaborative Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Artificial Intelligence Pattern Recognition software.

CTEPH can be difficult to diagnose because its symptoms are similar to asthma and chronic obstructive pulmonary disease symptoms. CTEPH affects five people per million annually worldwide. Computed tomography pulmonary angiography and a ventilation/perfusion scan can be used to determine if thromboembolic occlusion is causing pulmonary hypertension in patients.

Get the full story on our sister site, Medical Design & Outsourcing.

The post FDA grants breakthrough status to joint Merck-Bayer AI program appeared first on MassDevice.

Study: Heat-stable drug formulation offers new option to prevent postpartum bleeding

Data from a collaboration between Ferring PharmaceuticalsMerck (NYSE:MRK) and the World Health Organization showed that a heat-stable formulation of carbetocin is as effective as oxytocin for the prevention of excessive bleeding following vaginal birth.

Millions of women are affected by postpartum hemorrhage every year, according to Ferring Pharmaceuticals. Traditionally, women are given oxytocin to prevent the deadly condition. But oxytocin has to be stored and transported at 2 – 8°C, which is not always possible in countries where adequate storage and distribution resources are scarce.

Get the full story at our sister site, Drug Delivery Business News.

The post Study: Heat-stable drug formulation offers new option to prevent postpartum bleeding appeared first on MassDevice.

OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial

OncoSec Medical (NSDQ:ONCS) expanded its relationship with Merck (NYSE:MRK) today, announcing a deal to combine its ImmunoPulse IL-12 device with Merck’s anti-PD-1 therapy, Keytruda, in a Phase II trial of patients with triple negative breast cancer.

The trial is slated to study the drug-device combination in patients with inoperable locally advanced or metastatic cancer who have failed at least one systemic chemotherapy or immunotherapy.

Get the full story at our sister site, Drug Delivery Business News.

The post OncoSec to combine ImmunoPulse device with Merck’s immunotherapy in breast cancer trial appeared first on MassDevice.

Mass. Supremes: Pharma Cos. liable for generic labeling issues

Merck (NYSE:MRK) and other large brand-name pharmaceutical manufacturers could be legally liable for injuries resulting not from the use of their brand name products, but from generic versions of those drugs made by other companies, according to a new ruling from the Massachusetts Supreme Judicial Court.

The court ruling could set the precedent that such brand-name pharma companies could be found liable for reckless behavior if they fail to update labeling for their products which are also used for generic versions, according to court documents.

Read the whole story on our sister site, Drug Delivery Business

The post Mass. Supremes: Pharma Cos. liable for generic labeling issues appeared first on MassDevice.

Appeal board to review Sanofi’s Lantus insulin injection patents

  • 7 medical devices combating the opioid crisis

    Opioid-related deaths have become an epidemic in the US, garnering attention from the White House, the FDA and many other governmental bodies. From 2000 to 2014, nearly half a million Americans died from drug overdoses. In 2015, more than 50,000 people died from a drug overdoses, and 33,000 were opioid-related. Prescription overdoses continue to cause […]

  • Companion Medical launches smart insulin pen in U.S.

    Companion Medical started selling its smart insulin pen in the U.S. today, according to the San Diego, Calif.-based company. The InPen system, which combines an insulin injector pen and a smartphone app, is compatible with Eli Lilly‘s (NYSE:LLY) Humalog and Novo Nordisk‘s (NYSE:NVO) Novolog fast-acting insulin. Get the full story at our sister site, Drug Delivery Business News. […]

  • Manufacturing companies form collaborative for advancing product development capabilities

    A group of manufacturing services companies said today they created a collaboration, called the Medical Device Development Collaborative, to help improve access to a full range of product development capabilities for concept-to-market solutions. The collaboration is based in the Medical Alley region and aims to help small to mid-size OEMs by offering experience and expertise […]

  • Millar offloads telemetry product line to Kaha Sciences

    Medical device and OEM company Millar said today it is selling its lifesciences telemetry product division to New Zealand-based Kaha Sciences. Houston-based Millar said the divestiture comes as the company looks to focus its efforts on the clinical and OEM business segments in a strategy that emerged earlier this year. Kaha Sciences has picked up a handful […]

  • InstruSafe and Senhance Surgical Robotic System partner to launch instrument trays

    Summit Medical’s InstruSafe and TransEnterix’s Senhance Surgical Robotic System  have forged a partnership to launch two new surgical instrument trays for use with the robotic platform. The two new trays will include an instrument tray an an endoscopic adapter tray, both of which have been validated for the Senhance instrumentation. “We are excited to expand our product offering […]

  • New FDA guidance for dual submission 510(k) and CLIA waiver application for IVD companies

    By Stewart Eisenhart, Emergo Group New guidance from the US Food and Drug Administration explains requirements for in vitro diagnostic manufacturers to register for premarket notification using the agency’s Dual 510(k) and Clinical Laboratory Improvement Amendments (CLIA) Waiver by Application. Get the full story here at the Emergo Group’s blog. The opinions expressed in this […]

  • Researchers create ultrasound-sensor powered prosthetic hand with individual digit control

    Researchers are one step closer to creating a prosthetic hand that allows users to have full control over each finger, according to a new report from Georgia Tech. Researchers at the university say they have created an ultrasonic sensor which allows amputees to control individual fingers on a prosthetic hand, with enough sensitivity to play […]

  • Medline acquires Centurion Medical Products

    Medline recently completed its previously announced acquisition of Centurion Medical Products – boosting offerings around the Medline Erase BSI line access and dressing change bundles. Financial terms of the deal were not disclosed. Medline’s Erase BSI is meant to standardize best practices around central lines post-insertion, reducing cases of bloodstream infections. On top of its minor procedure trays, Centurion makes vascular insertion […]

  • Cadence expands laser processing capabilities

    Cadence has expanded its laser processing technologies with a new CL900 Cincinnati laser cutting machine. The new 4,000W fiber laser cutter adds to Cadence’s modified tube cutting lasers and completely custom flat sheet cutting lasers, Cadence announced yesterday. It also has the ability to cut 1,000 in. per minute (IPM) with a positioning accuracy of +/-0.001 […]

  • These artificial heart muscle patches can repair dead heart muscles

    A team of biomedical engineers have developed a fully functioning artificial human heart muscle that can be used as a patch to repair dead heart muscle. Duke University biomedical engineers developed the patch to be used in human patients who have previously suffered a heart attack. “Right now, virtually all existing therapies are aimed at […]

  • How to think outside the box with medtech innovation

    Innovation is important in medtech and many other industries. But what does it really mean – and can it be done with speed? That was the question that a panel of experts – moderated by William Betten of Betten Solutions – grappled with today at DeviceTalks West in Orange County, Calif. It turns out that […]

  • Startup aims to disrupt asthma, COPD space with digital inhaler

  • How a versatile epoxy is enabling brain stimulation

    Rohit Ramnath, Senior Product Engineer, Master Bond In but another example of how useful and critical epoxies can be, researchers in Israel used a two-part epoxy to construct a magnetic coil to stimulate animal brain neurons via a magnetic field. Designers of medical electronics assemblies have many options to choose from when selecting one or […]

  • Pros and cons of MDNR and MDMA medical device registration in Saudi Arabia

    By Stewart Eisenhart, Emergo Group Now that Saudi Arabian medical device regulators have exempted some low-risk products from full registration requirements, qualifying manufacturers should consider whether standard or fast-track access to the Saudi market best suits their business needs. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog […]

  • How middleware is changing medtech

    Medtech developers can take advantage of middleware technology to gain a competitive advantage. By Tim Gee, principal of Medical Connectivity Two macro trends are affecting how medical devices and systems are designed: Adoption of off-the-shelf (OTS) computing technology to extend the power and capabilities of traditional embedded system medical devices; and the evolution of software […]

  • How have medtech launches and prototyping evolved with 3D printing?

    Here are three basic ways that 3D printing can help you get your medical device project off the ground. Jim Medsker, Keystone Solutions Group Additive manufacturing, commonly referred to as 3D printing, began to surface in the 1980s. Since then, the technology has quickly become a valuable tool for creating plastic prototype parts in a rapid […]

  • Appirio launches solutions for Salesforce Lightning Bolt

    Wipro company Appirio recently launched new solutions that are built on Salesforce Lightning to deliver personalized and industry-specific services. The solutions that the company is ordering are all Lightning Bolts which are frameworks that allow companies to create functional and customer-facing websites. It is designed to increase collaboration and communication during crucial interaction points while […]

  • Sterigenics parent company is now Sotera Health

    Sterigenics International said today that it has changed the name of its parent company to Sotera Health, with Nelson Labs, Nordion and Sterigenics as Sotera’s three operating companies. The new name drew its inspiration from the name of the Greek goddess of safety, Soteria, and is meant to reflect the company’s commitment to global health. […]

  • Scapa Healthcare introducing new ultra-flexible silicone gel adhesive

    Scapa Healthcare – maker of skin-friendly adhesives – will introduce its new ultra-flexible Scapa Soft-Pro Silicone Gel 6058 at the 2017 Medica Trade Fair, Nov. 13–16 in Düsseldorf, Germany. The Silicone Gel 6058 is the most flexible silicone in Scapa’s product portfolio, according to the Windsor, Conn.–based company. It is conformable and contours to challenging anatomical […]

  • Chesapeake IRB, Schulman IRB merge to form Advarra

    Chesapeake IRB and Schulman IRB have merged to form Advarra, a new provider of IRB, institutional biosafety committee (IBC) and research compliance services. “By coming together as Advarra, we are merging the highest quality review organizations in the industry,” Jeffrey Wendel, president and CEO of Chesapeake IRB said. “Through a customer-centric integration, we will be […]

  • Greenlight Guru adds Grow to quality management software platform

    Greenlight Guru recently announced the introduction of its Grow software product to assist medical device companies with quality management after product launch. The Indianapolis-based company’s first product, Go, focused on helping medtech companies utilize design control, risk management and document management software to bring FDA and ISO-compliant medical devices to market in less time. Many […]

  • Enhancing catheter steerability and deflection

    It’s all in the tip when it comes to making catheters with state-of-the-art steerability and deflection. Andy Black and Tanner Hargens, Medical Murray Steerable catheters Catheters often need to navigate tortuous anatomy with precise control of the catheter tip. Steerable catheters are often utilized for access into side branches from parent vessels to introduce guidewires […]

  • Report: Q3 medical device recalls down 39%

    Medical device recalls have declined 39% for the third quarter, settling at 167, the lowest quarter the US has seen since the fourth quarter of 2011, according to a new Stericycle Expert Solutions report. Recalled units were up, however, rising 1% to 68 million which positioned it higher than 16 of the last 19 quarters, […]

  • Merck raises full-year guidance despite mixed Q3

  • Integer posts street-beating Q3

    Integer today posted third quarter earnings that beat expectations on Wall Street. The Frisco, Texas-based company posted profits of $13.7 million, of 43¢ per share, on sales of $363.3 million for the 3 months ended September 29, seeing bottom-line growth of 19.5% while sales grew 4.8% compared to the same period last year. Adjusted to […]

  • Flex posts Q2 FY2018 earnings beat

    Flex today posted second quarter 2018 earnings results that met expectations on Wall Street. The San Jose, Calif.-based company posted profits of $205.1 million, or 38¢ per share, on sales of $6.3 billion for the 3 months ended September 30, seeing the bottom line swing from $2.5 million in the red while sales grew 4.4% […]

  • Validation and testing: What you need to know

    James Woods, Senior Research Scientist, Jordi Labs In an increasingly competitive medical device industry, it’s still important that validation and testing is done right. Here are four things to keep in mind. Medical device industry leaders these days are driving results at an ever-increasing pace. Amid patent limitations, intense competition and acute regulatory scrutiny, there’s […]

  • Raumedic to present polymer solutions at Compamed and Medica

    Raumedic will be presenting its polymer solutions for medical and pharmaceutical applications at Compamed and Medica on Nov. 13-16 in Düsseldorf, Germany. The company is showcasing its highly flexible, high-pressure tubing that is used for angiography as well as its disposable cartridges for wearable drug delivery systems. High-pressure tubing for angioplasty needs to have optimal […]

  • Navigating the FDA for connected devices

    Aiden Petrie, Chief Innovation Officer, Emeritus, Ximedica As connectivity features become increasingly prevalent, developers are tasked with accounting for regulatory implications in increasingly long-term plans. Let’s imagine a product that dispenses a drug for eczema. At its most basic, the dispenser is little more than a package for the primary drug container and so falls […]

  • Tegra Medical touts toolmaker apprentice program

    Tegra Medical is touting its toolmaker apprentice program to help build its skilled manufacturing workforce. The apprentice program is a four-year program that requires participants to be enrolled in a local engineering program. Tegra Medical will pay their tuition and salary in return. The opportunity allows for apprentices to start their careers in toolmaking. Nick […]

  • Icon shares rise on Q3 beat-and-raise

    Shares in Icon rose today after the company beat expectations on Wall Street with its third quarter earnings results. The Dublin, Ireland-based company posted profits of $74.2 million, or $1.35 per share, on sales of $440.3 million for the 3 months ended September 30, seeing bottom-line growth of 10% while sales grew 4.8% compared with […]

  • The top 10 medical disruptors of 2018

    Each year the Cleveland Clinic determines what the top 10 disruptors in healthcare will be for the following year. The criteria to be considered a disruptor is that it has to be so innovative that it could change healthcare in a significant way in the next year. Approximately 150 to 200 Cleveland Clinic physicians from […]

  • Proto Labs gains on Q3 sales, earnings beats

    Shares in Proto Labs (NSDQ:PRLB) are up today after the contract manufacturer beat the consensus forecast on Wall Street for its third-quarter sales and earnings. Maple Plain, Minn.-based Proto Labs posted profits of $13.2 million, or 49¢ per share, on sales of $88.1 million for the three months ended Sept. 30, for a bottom-line gain […]

  • Factory CRO acquires MileStone Research Organization

    Factory CRO announced that it has acquired MileStone Research Organization. The financial details of the deal were not disclosed. “The merger with MileStone is an important step in building Factory’s operational strength and service range in North America,” Dirk Meijer, Factory CRO’s CEO, said. “MileStone is an excellent fit therapeutically, as well as culturally, and […]

  • Overmolding silicone onto thermoplastics: what you need for success

    David Mulera, VP, Engineering, MedPlast Overmolding silicone onto thermoplastics can be challenging, but offers advantages over TPEs that include chemical resistance, tensile strength, and compression set. Here are some best practices to maximize your success. Overmolding has become a fundamental technique for medical component manufacturers in recent years. It reduces assembly costs, improves quality and […]

  • At the intersection of cancer treatment and technology, it’s more evolution than revolution

    For the first time at SXSW, a series of panel discussions in the health track zoomed in on cancer — Connect to End Cancer. The themes that dominated tended to be the role of technology such as telemedicine and data from connected devices, the role of 5G technology and technology’s shortcomings. But concerns over what Trump’s FDA nominee will do with the FDA cast a long shadow over parts of the discussion.

    Here were some of the more interesting conversation points across a couple of the panel discussions I attended.

     Telemedicine, telehealth and the impact of 5G

    Advertisement

    Most people don’t think of cancer treatment and telemedicine intersecting but as Rebecca Kaul, Houston-based MD Anderson Chief Innovation Officer noted, cancer center patients tend to have a varied geographical base. “We think telemedicine is highly important — two-thirds of our patients come from outside of Texas.”

    John Donovan, AT&T Chief Strategy Officer and group president for AT&T Technology and Operations, noted that 5G had the potential to improve the quality of virtual interactions between patients and physicians.

    5G will improve the quality of technology execution from telemedicine from near real time to real time, he noted. Donovan pointed out that healthcare is one of several industries hindered by slow technology. This advancement could help not only healthcare but other industries as well such as fintech.

    Coping with technology shortcomings

    Another interesting part was when the discussion tackled some of the shortcomings of technology, particularly when our expectations can’t be matched by the reality on the ground. Greg Simon, director of the Biden Cancer Initiative at the Biden Foundation, defended platforms like IBM Watson by noting that even the Hubble space telescope when initially launched had blurry vision. It took a team of scientists to correct that.  The computer platform is not a panacea because one of the challenges of new technology is that it takes time before it rises to its potential.

    “It’s not that surprising that Watson isn’t perfect,” Simon noted. “It is still a student. It reads everything but it doesn’t know everything.”

    Aman Bhandari, Merck executive director of data, sciences and partnerships, observed that there is dissonance between what we have the ability to do and what is actually happening in the healthcare delivery system.

    “So much great innovation is happening, yet our current health delivery system isn’t working to make those innovations available to everyone,” Bhandari said.

    Even immunotherapy, which is a hot area of investment for venture capital and is regarded as a promising new technology, has its own set of shortcomings. The problem with immunotherapy is that it can attack healthy tissue as well as unhealthy tissue.

    Big data and interoperability often rise to the surface as obstacles in healthcare and these sessions were no exception. In a lightning round for a panel moderated by Halle Tecco, who founded Rock Health and now teaches a class at Columbia Business School, she asked panelists what’s the biggest challenge they currently face. Bhandari noted data liquidity and Tecco’s husband Jeff Hammerbacher, the cofounder of Cloudera, called attention to the “Tower of Babel” around data.

    Every regulation at the FDA has been written in blood

    With speculation that President Donald Trump’s nomination to head up the U.S. Food and Drug Administration will champion deregulation, several of the panelists in one session feared what the consequences might be. Simon and Bhandari touched on the evolution of the FDA.

    “Every regulation at the FDA has been written in blood,” said Simon solemnly. “You will not hear from the cancer community that the FDA is slow and burdensome.”

    Bhandari added, “Every major regulation has happened because of a public health concern.”

    Simon expressed the hope that the administration would steer clear of cancer initiatives that have already been launched.

    Another panelist expressed the hope that providing better education support to patients about particular clinical trials would help with poor recruitment efforts.

    Simon was also frustrated by the way data from clinical trials is not released until one year after the clinical study was finished and hoped that would change.

    Advice for startups

    Tecco also asked her panel to offer some advice for startups. At some point in the conversation, Bhandari expressed some frustration with startups that make AI and machine learning claims without providing a more nuanced approach to how they are using these tools or even noting the slight differences between the two. Machine learning is one aspect of AI, which is a much broader term.

    Simon advised entrepreneurs to “immerse yourself in patients” and focus on their interests and priorities rather than investors, adding:

    “Don’t think about investors or the markets — if you immerse yourself in patients, you will figure something out.”

    Photo: xrisca30, Getty Images,